Comparison · NCT01652469-sae
A: Erlotinib vs B: Docetaxel: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. A: Erlotinib vs B: Docetaxel: serious adverse events. Trial comparisons, record NCT01652469-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01652469-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.184 | 0.0922 | 0.334 | wilson | |
| Risk in group 2 | 0.463 | 0.321 | 0.613 | wilson | |
| Risk difference, group 1 minus group 2 | -0.279 | -0.454 | -0.0721 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.398 | 0.189 | 0.838 | log | |
| Odds ratio, group 1 over group 2 | 0.261 | 0.0939 | 0.728 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on A: Erlotinib than on B: Docetaxel | 3.58 | 2.2 | 13.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | A: Erlotinib | Erlotinib in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.~Erlotinib: Erlotinib 150 mg/day p.o. continuously with 21 days cycle. | 7 | 38 | EG000 |
| Group 2 | B: Docetaxel | Docetaxel in standard dose. Until progression (clinical or radiological) or unacceptable toxicity.~Docetaxel: Docetaxel 75 mg/m2 as an IV infusion every 21 days. | 19 | 41 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
- NCT number
- NCT01652469
- Phases
- PHASE3
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Erlotinib, Docetaxel
- Lead sponsor
- ETOP IBCSG Partners Foundation
- Results first posted
- 2019-08-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01652469?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01652469-sae